

Yassmin Moatasim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8214689/publications.pdf>

Version: 2024-02-01

38
papers

1,195
citations

331670

21
h-index

395702

33
g-index

39
all docs

39
docs citations

39
times ranked

1491
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic and Antigenic Characteristics of Highly Pathogenic Avian Influenza A(H5N8) Viruses Circulating in Domestic Poultry in Egypt, 2017–2021. <i>Microorganisms</i> , 2022, 10, 595.	3.6	13
2	In Vitro and In Vivo Antiviral Studies of New Heteroannulated 1,2,3-Triazole Glycosides Targeting the Neuraminidase of Influenza A Viruses. <i>Pharmaceuticals</i> , 2022, 15, 351.	3.8	10
3	Scrutinizing the Feasibility of Nonionic Surfactants to Form Isotropic Bicelles of Curcumin: a Potential Antiviral Candidate Against COVID-19. <i>AAPS PharmSciTech</i> , 2022, 23, 44.	3.3	30
4	Antiviral activity of chitosan nanoparticles encapsulating silymarin (Si–CNPs) against SARS-CoV-2 (<i>in silico</i> and <i>in vitro</i> study). <i>RSC Advances</i> , 2022, 12, 15775-15786.	3.6	16
5	Insights into Genetic Characteristics and Virological Features of Endemic Avian Influenza A (H9N2) Viruses in Egypt from 2017–2021. <i>Viruses</i> , 2022, 14, 1484.	3.3	4
6	Lipid polymer hybrid nanocarriers as a combinatory platform for different anti-SARS-CoV-2 drugs supported by computational studies. <i>RSC Advances</i> , 2021, 11, 28876-28891.	3.6	4
7	Incidence, household transmission, and neutralizing antibody seroprevalence of Coronavirus Disease 2019 in Egypt: Results of a community-based cohort. <i>PLoS Pathogens</i> , 2021, 17, e1009413.	4.7	21
8	Impact of Individual Viral Gene Segments from Influenza A/H5N8 Virus on the Protective Efficacy of Inactivated Subtype-Specific Influenza Vaccine. <i>Pathogens</i> , 2021, 10, 368.	2.8	3
9	Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies. <i>Vaccines</i> , 2021, 9, 214.	4.4	33
10	Structure- and Ligand-Based <i>in silico</i> Studies towards the Repurposing of Marine Bioactive Compounds to Target SARS-CoV-2. <i>Arabian Journal of Chemistry</i> , 2021, 14, 103092.	4.9	18
11	Cnicin as an Anti-SARS-CoV-2: An Integrated <i>In Silico</i> and <i>In Vitro</i> Approach for the Rapid Identification of Potential COVID-19 Therapeutics. <i>Antibiotics</i> , 2021, 10, 542.	3.7	16
12	Bioactive Polyphenolic Compounds Showing Strong Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus 2. <i>Pathogens</i> , 2021, 10, 758.	2.8	66
13	3-Alkenyl-2-oxindoles: Synthesis, antiproliferative and antiviral properties against SARS-CoV-2. <i>Bioorganic Chemistry</i> , 2021, 114, 105131.	4.1	23
14	New Pyrazine Conjugates: Synthesis, Computational Studies, and Antiviral Properties against SARS-CoV-2. <i>ChemMedChem</i> , 2021, 16, 3418-3427.	3.2	17
15	New quinoline-triazole conjugates: Synthesis, and antiviral properties against SARS-CoV-2. <i>Bioorganic Chemistry</i> , 2021, 114, 105117.	4.1	45
16	Delineating a potent antiviral activity of <i>Cuphea ignea</i> extract loaded nano-formulation against SARS-CoV-2: <i>In silico</i> and <i>in vitro</i> studies. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 66, 102845.	3.0	38
17	Synthesis of aspirin-curcumin mimic conjugates of potential antitumor and anti-SARS-CoV-2 properties. <i>Bioorganic Chemistry</i> , 2021, 117, 105466.	4.1	15
18	Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibodies in Egyptian Convalescent Plasma Donors. <i>Frontiers in Microbiology</i> , 2020, 11, 596851.	3.5	7

#	ARTICLE	IF	CITATIONS
19	FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2. <i>Pharmaceuticals</i> , 2020, 13, 443.	3.8	110
20	Coding-Complete Genome Sequences of Two SARS-CoV-2 Isolates from Egypt. <i>Microbiology Resource Announcements</i> , 2020, 9, .	0.6	44
21	Common childhood vaccines do not elicit a cross-reactive antibody response against SARS-CoV-2. <i>PLoS ONE</i> , 2020, 15, e0241471.	2.5	11
22	EGYVIR: An immunomodulatory herbal extract with potent antiviral activity against SARS-CoV-2. <i>PLoS ONE</i> , 2020, 15, e0241739.	2.5	32
23	Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Dromedary Camels in Africa and Middle East. <i>Viruses</i> , 2019, 11, 717.	3.3	38
24	Development of an effective contemporary trivalent avian influenza vaccine against circulating H5N1, H5N8, and H9N2 in Egypt. <i>Poultry Science</i> , 2019, 98, 6289-6295.	3.4	9
25	Comparative Virological and Pathogenic Characteristics of Avian Influenza H5N8 Viruses Detected in Wild Birds and Domestic Poultry in Egypt during the Winter of 2016/2017. <i>Viruses</i> , 2019, 11, 990.	3.3	13
26	Active surveillance and genetic evolution of avian influenza viruses in Egypt, 2016â€“2018. <i>Emerging Microbes and Infections</i> , 2019, 8, 1370-1382.	6.5	29
27	Middle East respiratory syndrome coronavirus infection in non-camelid domestic mammals. <i>Emerging Microbes and Infections</i> , 2019, 8, 103-108.	6.5	42
28	Isolation and Characterization of a Distinct Influenza A Virus from Egyptian Bats. <i>Journal of Virology</i> , 2019, 93, .	3.4	42
29	Single gene reassortment of highly pathogenic avian influenza A H5N1 in the low pathogenic H9N2 backbone and its impact on pathogenicity and infectivity of novel reassortant viruses. <i>Archives of Virology</i> , 2017, 162, 2959-2969.	2.1	11
30	Systematic, active surveillance for Middle East respiratory syndrome coronavirus in camels in Egypt. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-7.	6.5	55
31	Synthesis and Anti-Influenza Virus Activity of Novel bis(4-chromene-3-carbonitrile) Derivatives. <i>Journal of Heterocyclic Chemistry</i> , 2017, 54, 1854-1862.	2.6	47
32	Novel reassortant H9N2 viruses in pigeons and evidence for antigenic diversity of H9N2 viruses isolated from quails in Egypt. <i>Journal of General Virology</i> , 2017, 98, 548-562.	2.9	44
33	Genetic characterization of highly pathogenic avian influenza A H5N8 viruses isolated from wild birds in Egypt. <i>Journal of General Virology</i> , 2017, 98, 1573-1586.	2.9	54
34	Generation of a reassortant avian influenza virus H5N2 vaccine strain capable of protecting chickens against infection with Egyptian H5N1 and H9N2 viruses. <i>Vaccine</i> , 2016, 34, 218-224.	3.8	13
35	Active Surveillance for Avian Influenza Virus, Egypt, 2010â€“2012. <i>Emerging Infectious Diseases</i> , 2014, 20, 542-551.	4.3	71
36	Molecular characterization of avian influenza H5N1 virus in Egypt and the emergence of a novel endemic subclade. <i>Journal of General Virology</i> , 2014, 95, 1444-1463.	2.9	46

#	ARTICLE	IF	CITATIONS
37	Genetic and antigenic evolution of H9N2 avian influenza viruses circulating in Egypt between 2011 and 2013. Archives of Virology, 2014, 159, 2861-2876.	2.1	58
38	Characterization of the recent outbreak of foot-and-mouth disease virus serotype SAT2 in Egypt. Archives of Virology, 2013, 158, 619-627.	2.1	47